Highest-materiality recent filing
American Well stockholders re-elect Ido Schoenberg, ratify PwC, approve say-on-pay
Class III director Dr. Ido Schoenberg elected with 20,509,462 votes for, 954,941 withheld, 2,507,946 broker non-votes.
Co-founder and EVP Chairman Roy Schoenberg resigns from board effective May 6, 2026
Dr. Roy Schoenberg resigned as Board member and Executive Vice Chairman effective May 6, 2026.
Amwell beats Q1 revenue guidance at $54.9M; net loss narrows to $10.3M
Q1 revenue $54.9M exceeds guidance; subscription $24.9M, AMG visit revenue $28.9M.
Director Dr. Peter Slavin to resign from American Well board at 2026 annual meeting
Dr. Peter Slavin notified resignation from Board, effective at next annual meeting in 2026.
Q4 total revenue $55.3M exceeded guidance; subscription rev $28.8M, AMG visit rev $23.7M.
American Well extends digital care platform partnership with Elevance through Jan 2029
Entered 3-year Amended SOW effective Jan 1, 2026, replacing prior 2023 agreement with Elevance Health.
Amwell extends Elevance Health partnership to 2029; adds AI provision
Master Services Agreement extended through Jan 1, 2029, auto-renewing annually thereafter.
Amwell Q3 revenue $56.3M beats guidance; net loss widens to $31.9M
Revenue $56.3M (subscription $30.9M, AMG visits $21.2M) exceeded prior Q2 guidance.
Amwell Q2 revenue $70.9M, net loss $19.5M; cuts FY2025 revenue guidance to $245M-$250M
Revenue $70.9M (subscription $40.4M, AMG visits $22.8M); gross margin 56.1%.
Director Stephen Schlegel elected with 18,018,064 votes for and 2,216,772 withheld.
Amwell Q1 2025 revenue $66.8M; net loss narrows to $18.4M vs $44.6M prior quarter
Total revenue $66.8M (subscription $32.2M, AMG visits $26.6M); gross margin 53%.
Amwell appoints Dan Zamansky as CPTO; Vaughn Paunovich departs March 2, 2025
Dan Zamansky named chief product and technology officer, effective March 3, 2025.
Amwell Q4 revenue $71M, net loss $44.6M; FY2025 revenue guidance $250-260M, adj EBITDA -$45 to -$55M
Q4 2024: total revenue $71.0M (subscr $36.9M, AMG visits $29.2M), gross margin 48%.
Amwell sells telepsychiatry business to Avel eCare for $21M cash plus earn-out
Upfront cash $20.7M (1.1x trailing 12-month revenue) plus earn-out of 0.4x next 12-month revenues.
Amwell CFO Mark Hirschhorn adds COO role; two senior executives depart
Hirschhorn to serve as both CFO and COO effective Jan. 1, 2025; salary increased to $575,000, bonus target 125%.
American Well adopts inducement plan, grants $2.5M RSU and $5M LTIP to new CFO Hirschhorn
2024 Inducement Plan adopted effective Nov 4, 2024; 1,222,960 shares reserved for inducement awards.
Q3 revenue $61.0M (subscription $26.2M, AMG visit revenue $27.5M); gross margin 37%.
Amwell CFO Robert Shepardson resigns; Mark Hirschhorn appointed CFO effective Oct 21
Shepardson resigns effective Oct 18, 2024; no disagreement with company operations.
American Well amends CCO Weiler's contract; adds severance for voluntary exit after June 2025
CCO Weiler gets one-year base salary severance, pro-rata bonus, and equity vest continuation if she voluntarily resigns without Good Reason after June 1, 2025.
Amwell Q2 2024 revenue $62.8M, net loss $49.9M; narrows FY adjusted EBITDA loss guidance
Total revenue $62.8M, subscription $27.5M, AMG visit revenue $28.7M; gross margin 37%.
American Well (AMWL) effects 1-for-20 reverse stock split effective July 10, 2024
Reverse stock split at 1-for-20 ratio executed on July 10, 2024 at 5:00 p.m. ET.
Amwell announces 1-for-20 reverse stock split to regain NYSE compliance
Board approved 1-for-20 reverse split effective July 10, 2024; trading begins July 11 under AMWL.
American Well shareholders elect three Class I directors, approve reverse stock split
Derek Ross, Deborah Jackson, Rob Webb elected as Class I directors for terms expiring 2027.
Amwell appoints former Morgan Stanley MD Ricky Goldwasser to board, replacing Deval Patrick
Goldwasser appointed as Class II director effective June 13, 2024; term ends at 2025 annual meeting.
Amwell co-CEO Roy Schoenberg becomes Executive Vice Chairman; Ido Schoenberg sole CEO
Roy Schoenberg resigned as President & Co-CEO effective June 13, 2024, appointed Executive Vice Chairman.
Amwell Q1 2024 revenue $59.5M, net loss widens to $73.4M; guides 2025 rev $335-350M
Q1 revenue of $59.5M (subscription $24.9M, AMG visit revenue $31.1M); gross margin 31%.
American Well (AMWL) receives NYSE delisting notice for non-compliance with $1 minimum bid price
On April 2, 2024, received NYSE notice that average closing price of AMWL common stock was below $1 per share over 30 consecutive trading-days.
Amwell Q4 revenue $70.7M; net loss narrows to $50M; guides to 2026 EBITDA breakeven
Q4 2023 total revenue $70.7M (subscription $27.3M, AMG visits $32.1M); gross margin 34%.
Director Deval Patrick to resign from American Well board effective 2024 annual meeting
Deval Patrick notified resignation from Board effective date of next annual meeting in 2024.
Amwell Q3 revenue $61.9M, net loss $137.1M includes $78.9M goodwill impairment; guidance revised
Revenue $61.9M (subscription $28.4M, AMG visit revenue $26.7M); gross margin 35%.
Amwell Q2 revenue $62.4M, net loss $93.5M; cuts FY revenue guidance to $257-263M
Revenue $62.4M ($28.0M subscription, $28.1M AMG visits); gross margin 39%.
Dr. Peter Slavin, Dr. Ido Schoenberg, Dr. Roy Schoenberg elected as Class III directors with >335M votes each.
Amwell Q1 revenue $64M; net loss $398.5M with $330.3M goodwill impairment
Revenue $64.0M (subscription $28.7M, AMG visits $32.5M); gross margin 39.5%.
Q4 2022 revenue $79.2M, up 9% YoY; subscription revenue $30.7M, AMG visit revenue $35.1M.
MSA and related provider agreements effective Jan 1, 2023; initial 3-year term through Dec 31, 2025.
Total revenue $69.2M, up 11% YoY; subscription revenue $31.9M, up 19% YoY.
Amwell appoints Robert Webb to Board of Directors effective October 31, 2022
Robert Webb appointed as Class I director; term ends at 2024 annual meeting.
CFO Robert Shepardson title changed to EVP and CFO; severance: unvested equity vests through first anniversary of termination.
Amwell Q2 revenue $64.5M (+7% YoY); adjusted EBITDA loss narrows to $42.8M
Revenue $64.5M (+7% YoY); subscription $29.6M (+10%), AMG visits $29.7M (+8%).
American Well stockholders elect three Class II directors and ratify PwC as auditor
Stockholders elected Deval Patrick (321.5M for), Stephen Schlegel (316.0M for), and Toby Cosgrove (330.3M for) as Class II directors.
American Well Chief Commercial & Growth Officer Brendan O'Grady resigns effective June 3, 2022
Brendan O'Grady resigns as Chief Commercial & Growth Officer, effective June 3, 2022.
American Well grants co-CEOs PSUs of 1M target shares each, tied to market cap milestones up to 750%
Each co-CEO (Ido Schoenberg, Roy Schoenberg) receives 1M target PSUs; maximum payout 7.5M shares at 500% market cap growth.
American Well issues 4.96M shares to former SilverCloud shareholders in lieu of earn-out
Issued 4,959,856 shares of Class A common stock to former SilverCloud shareholders in lieu of earn-out payment.
Amwell Q1 revenue up 11% to $64.2M; net loss widens to $70.3M vs $39.8M
Revenue $64.2M (+11% YoY); subscription $28.7M, visit $30.7M.
American Well enters new employment agreement with President of International, Phyllis Gotlib
Annual salary of $485,000, with 10% designated as special compensation for non-compete/confidentiality.
American Well grants $2.1M PSUs each to three named execs under new market-cap-based LTI program
Named execs (Gotlib, Knight, Shepardson) each granted $2.1M in PSUs tied to market cap milestones; vesting 2022-2025.
American Well Corp reports Q4 and full year 2021 results, provides 2022 guidance
Q4 2021 revenue $72.8M, up from $60.4M in Q4 2020; full year revenue $252.8M vs $245.3M.
Amwell Q3 revenue $62.2M, net loss improves to $50.9M; guides 2021 revenue lower, EBITDA higher
Revenue $62.2M vs $62.6M YoY; subscription revenue $26.7M (+3.5%), visit revenue $30.0M (+5.3%).
Dr. Roy Schoenberg notified American Well Corporation (the “Company”) of his resignation from the Company’s Board of Directors, effective immediately.
Mr. Paunovich’s employment with the Company will end on March 2, 2025.
Effective November 4, 2024, the Company will grant awards to its new Chief Financial Officer, Mark Hirschhorn, under the Inducement Plan.
Mr. Robert Shepardson informed American Well Corporation (the “Company”) of his intention to resign as Chief Financial Officer (“CFO”), effective October 18, 2024.
the Board of Directors of the Company (the “Board”) appointed Mark Hirschhorn to serve as the Company’s CFO, effective October 21, 2024
On June 13, 2024, the Board of Directors (the "Board") of American Well Corporation (the "Company") appointed Rivka "Ricky" Goldwasser as a Class II director of the Company.
Dr. Roy Schoenberg resigned as the President & Co-Chief Executive Officer of American Well Corporation (the “Company”), effective June 13, 2024. Dr. Schoenberg’s decision to resign was related to his appointment as our Executive Vice Chairman
On December 21, 2023, Deval Patrick notified American Well Corporation (the “Company”) that he will resign from the Board of Directors, effective on the date of the Company’s next annual meeting of stockholders to be held in 2024.
Effective October 31, 2022, the Board of Directors (the " Board ") of American Well Corporation (the " Company ") appointed Robert Webb as a Class I director of the Company.
Pursuant to the Shepardson Amendment, Mr. Shepardson’s title was changed to EVP and Chief Financial Officer.
Pursuant to the Gotlib Amendment, Ms. Gotlib’s title was changed to EVP and President, American Well International.
Pursuant to the Knight Amendment, Mr. Knight’s title was changed to EVP and Chief Operating Officer.
Max materiality 0.90 · Median 0.60 · Most common event earnings